Market Still Looks Good, Even With Reversal<br /><br />By Rev Shark<br />RealMoney.com Contributor<br />4/7/2008 4:34 PM EDT<br /><br />Although the indices closed around flat on the day, there were a lot of big reversals in some of the recent momentum favorites. Solar energy, steels and agricultural chemicals all opened very hot and then saw selling pressure most of the day. Given how far some of the hot groups have moved recently, some profit-taking was bound to kick in, especially when the emotions were running so high this morning.<br /> <br />Even with some rather dramatic reversals, the market continues to look pretty good technically. We are holding up, even though we are somewhat extended at this point. However, I'd like to see better volume. I'm concerned that it has been so light, as this market has run over the last couple weeks. We are not seeing big institutional accumulation, and that makes the underlying support a bit uncertain. At some point, to make this move convincing, we need better volume. <br /><br />Despite some negatives under the surface, the bulls continue to have the benefit of the doubt because they are holding up so well. We've had plenty of good excuses for some profit-taking to accelerate, and it just hasn't happened. There seem to be some underlying support among underinvested bulls and that holds the seeds of further upside. <br /><br /><br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: NTRI +16.5%, NUAN +3.1%, VRSN +2.0% (also Brian Robins named acting CEO), CHTT +1.8%, CHINA +1.4%... Other news: RGEN +22.7% (announces settlement with Bristol-Myers Squibb in Orencia lawsuit), AGEN +22.3% (announces that the Russian Ministry of Public Health has issued a registration certificate for the use of Oncophage in the treatment of kidney cancer patients at intermediate risk for disease recurrence), VRNM +4.9% (announces commencement of start-up phase at its demonstration-scale cellulosic ethanol plant), ANSV +4.1% (announces that a pivotal Phase 3 clinical trial evaluating Adlea is underway), ATAC +3.5% (will replace MESA in the S&P SmallCap 600 after the close on 4/9), ISIS +3.0% (Bristol-Myers Squibb selects ISIS drug targeting PCSK9 as development candidate for prevention and treatment of cardiovascular disease), TIN +3.0% (Cramer makes positive comments on MadMoney), PXD +2.8% (raises long-term production growth target to 14+% and increases net resource potential by 1.1 bln barrels oil equivalent), FMX +2.2% (Cramer makes positive comments on MadMoney), INSU +1.9% (completes review of strategic options; determines to execute business plan and hire new CEO), ELN +1.9% (still checking), CRXL +1.8% (announces a non-exclusive STAR research license agreement with Celltrion for the production of recombinant proteins), ITG +1.5% (says March 2008 US trading volume was 4.6 billion shares), UN +1.1% (still checking)... Analyst upgrades: FNM +2.8% (upgraded to Overweight at Lehman), PSUN +2.7% (upgraded to Outperform at Wachovia), FRE +2.6% (upgraded to Overweight at Lehman), IVAC +2.1% (upgraded to Buy at Brean Murray), NYX +1.6% (upgraded to Buy at tier 1 firm), AXP +1.6% (upgraded to Buy at tier 1 firm), NVS +1.3% (upgraded to Neutral at HSBC).<br /><br />Allapoole avanevad:<br /><br />In reaction to weak earnings/guidance: CBBO -7.4%, SCUR -7.1%, NVLS -4.6%, LDK -2.5% (also announces proposed offering of us$300 million senior convertible notes), AMD -2.2%, AUO -2.1%, AA -1.9%, MNTG -1.4%... Select financial names showing weakness: BCS -3.8%, LYG -3.4%, CIT -3.3%, STD -1.8%, HBC -1.1%, DB -1.0%... Other news: GRO -46.1% (announces resignation of COO and retracts prior guidance), FMD -31.8% (makes statement on TERI's petition for reorganization under Chapter 11; says is analyzing the implications of this filing), REXX -8.1% (files S-1 relating to 8 mln share offering by co selling 4 mln shares of common stock and the selling stockholders are selling 4 mln shares of common stock), MWE -5.6% (announces public offering of 5 mln common units at $32.44/unit), ASML -5.6% (down in sympathy with AMD), WM -5.3% (finalizing capital injection plan and downgraded to Underperform at Keefe Bruyette), SIRF -5.0% (discloses CFO resignation), ENDP -3.0% (announced that it has notified the FDA of the withdrawal of the sNDA without prejudice for FROVA), DEPO -2.0% (settles patent litigation against IVAX and as stated that it intends to return the rights to Chronogesic licensed from DURECT), RTP -1.7% and BHP -1.5% (Rio Tinto can go it alone, CEO says - Globe and Mail)... Analyst downgrades: IFX -6.5% (downgraded to Neutral at Credit Suisse), GRMN -5.1% (downgraded to Hold at Soleil), MI -4.2% (downgraded to Sell at tier 1 firm), JBL -4.0% (Hearing downgraded to Neutral from Buy at tier 1 firm), FLS -3.9% (downgraded to Neutral at Baird), AZN -2.9% (downgraded to Neutral at tier 1 firm), NITE -2.4% (hearing downgraded to Neutral at tier 1 firm), CNK -2.2% (downgraded to Neutral at JPMorgan).